{"api":"v1","generated_at":"2026-10-02T07:48:51.543Z","licence":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"TOLL, with a link to the page cited"},"page":"https://tollindex.com/e/api-magentlab-com-api-calc-hfa-icos-anthracycline-0120c0","pinned_page":"https://tollindex.com/e/api-magentlab-com-api-calc-hfa-icos-anthracycline-0120c0/at/2026-10-02T05-34Z","pinned":false,"method":"https://tollindex.com/ledger/method","snapshot_at":"2026-10-02T05:34:29.993Z","snapshot_stamp":"2026-10-02T05-34Z","endpoint":{"slug":"api-magentlab-com-api-calc-hfa-icos-anthracycline-0120c0","canonical_url":"https://api.magentlab.com/api/calc/hfa_icos_anthracycline","resource":"https://api.magentlab.com/api/calc/hfa_icos_anthracycline","http_method":"POST","type":"http","x402_version":2,"registries":["cdp"],"primary_registry":"cdp","curated_by_coinbase":false,"description":"Lyon 2020 HFA-ICOS baseline cardiovascular risk before anthracycline chemotherapy. Returns risk_level low, medium, high, or very_high from published Very high, High, Medium 2, and Medium 1 factors, plus medium_points and the paper's expert-opinion cardiotoxicity_guide. Age and LVEF use the highest matching printed band only. Caller assigns labs and BMI >30. magent does not examine the patient or read imaging. Not a medical device or treatment order.","service_name":"magent","declared_category":null,"declared_tags":["hfa-icos","anthracycline","cardio-oncology","hemodynamics","calculator"],"route_template":null,"registry_updated":"2026-09-28T13:45:06.884Z"},"derived":{"note":"fields no registry supplies; TOLL derives them and marks them derived on the page","title":"calc hfa icos anthracycline","category":"search","first_observed_by_toll":"2026-09-28T13:51:25.436Z","last_observed_by_toll":"2026-10-02T05:34:29.993Z","observation_began":"2026-09-10"},"presence":{"listed_now":true,"first_absent_at":null,"delisting_confirmed_at":null,"events":[{"registry":"cdp","at":"2026-09-28T13:51:25.437Z","event":"listed"}]},"accepts":[{"registry":"cdp","ordinal":0,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.005 USDC","amount_units":0.005,"decimals_known":true,"pay_to":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","scheme":"exact"}],"counters":{"observed_at":"2026-10-02T05:34:29.993Z","calls_30d":3,"unique_payers_30d":1,"last_called_at":"2026-09-28T13:45:06.757Z"},"validation":{"latest":{"observed_at":"2026-10-01T06:15:20.563Z","state":"pass","failed_checks":[],"endpoint_http_status":402,"run_id":"daily-2026-10-01"},"uptime":[{"days":7,"observed":5,"passed":5,"ratio":1},{"days":30,"observed":5,"passed":5,"ratio":1},{"days":90,"observed":5,"passed":5,"ratio":1}],"history_90d":[{"observed_at":"2026-10-01T06:15:20.563Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-01","state_changed":false},{"observed_at":"2026-09-30T04:20:57.097Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-30","state_changed":false},{"observed_at":"2026-09-29T17:54:39.158Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-29","state_changed":false},{"observed_at":"2026-09-28T16:51:43.346Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-28","state_changed":false},{"observed_at":"2026-09-28T14:09:06.570Z","state":"pass","failed_checks":[],"run_id":"new-after-daily-2026-09-28","state_changed":true}]},"seller":{"wallet":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","page":"https://tollindex.com/seller/0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","endpoints":844,"hosts":1},"reports":0,"registry_record":{"cdp":[{"tags":["hfa-icos","anthracycline","cardio-oncology","hemodynamics","calculator"],"type":"http","accepts":[{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2","paymentFlow":"upfront","resourceUrl":"https://api.magentlab.com/api/calc/hfa_icos_anthracycline","assetTransferMethod":"eip3009"},"payTo":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","amount":"5000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":600}],"quality":{"lastCalledAt":"2026-09-28T13:45:06.757Z","l30DaysTotalCalls":3,"l30DaysUniquePayers":1},"resource":"https://api.magentlab.com/api/calc/hfa_icos_anthracycline","extensions":{"bazaar":{"info":{"input":{"body":{"items":[{"ckd":false,"obesity":false,"diabetes":false,"age_years":50,"elevated_bnp":false,"hypertension":false,"lvef_percent":60,"stable_angina":false,"elevated_troponin":false,"previous_anthracycline":false,"current_or_significant_smoker":false,"severe_valvular_heart_disease":false,"heart_failure_or_cardiomyopathy":false,"mi_or_coronary_revascularization":false,"previous_non_anthracycline_chemo":false,"prior_left_chest_or_mediastinal_rt":false},{"ckd":false,"obesity":false,"diabetes":false,"age_years":50,"elevated_bnp":false,"hypertension":false,"lvef_percent":60,"stable_angina":false,"elevated_troponin":false,"previous_anthracycline":false,"current_or_significant_smoker":false,"severe_valvular_heart_disease":false,"heart_failure_or_cardiomyopathy":false,"mi_or_coronary_revascularization":false,"previous_non_anthracycline_chemo":false,"prior_left_chest_or_mediastinal_rt":false}]},"type":"http","method":"POST"},"output":{"type":"json","example":{"path":"/api/calc/hfa_icos_anthracycline","count":2,"items":[{"formula":"hfa_icos_anthracycline","citation":{"id":"lyon-2020","doi":"10.1002/ejhf.1920","pmid":"32458582","title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","source":"Eur J Heart Fail. 2020;22(11):1945-1960","authors":"Lyon AR, Dent S, Stanway S, et al."},"age_years":50,"components":[{"tier":"very_high","factor":"heart_failure_or_cardiomyopathy","points":0,"present":false},{"tier":"high","factor":"severe_valvular_heart_disease","points":0,"present":false},{"tier":"high","factor":"mi_or_coronary_revascularization","points":0,"present":false},{"tier":"high","factor":"stable_angina","points":0,"present":false},{"tier":"high","factor":"previous_anthracycline","points":0,"present":false},{"tier":"high","factor":"prior_left_chest_or_mediastinal_rt","points":0,"present":false},{"tier":"medium_1","factor":"elevated_troponin","points":0,"present":false},{"tier":"medium_1","factor":"elevated_bnp","points":0,"present":false},{"tier":"medium_1","factor":"hypertension","points":0,"present":false},{"tier":"medium_1","factor":"diabetes","points":0,"present":false},{"tier":"medium_1","factor":"ckd","points":0,"present":false},{"tier":"medium_1","factor":"previous_non_anthracycline_chemo","points":0,"present":false},{"tier":"medium_1","factor":"current_or_significant_smoker","points":0,"present":false},{"tier":"medium_1","factor":"obesity","points":0,"present":false},{"tier":"none","value":50,"factor":"age_years","points":0,"present":false},{"tier":"none","value":60,"factor":"lvef_percent","points":0,"present":false}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","risk_level":"low","lvef_percent":60,"medium_points":0,"formula_expression":"very_high if heart_failure_or_cardiomyopathy; else high if any High factor (severe_valvular_heart_disease, mi_or_coronary_revascularization, stable_angina, lvef_percent<50, age_years>=80, previous_anthracycline, prior_left_chest_or_mediastinal_rt) OR medium_points>=5; else medium if medium_points in 2..4; else low (no factors or one Medium 1). medium_points sums Medium 1 (=1: elevated_troponin, elevated_bnp, hypertension, diabetes, ckd, previous_non_anthracycline_chemo, current_or_significant_smoker, obesity) and Medium 2 (=2: lvef_percent 50-54, age_years 65-79) only. Age and LVEF use the highest matching printed band. Lyon 2020 HFA-ICOS anthracycline table. cardiotoxicity_guide is that paper's expert-opinion guide: low <2%, medium 2-9%, high 10-19%, very high >=20%","cardiotoxicity_guide":"<2%"},{"formula":"hfa_icos_anthracycline","citation":{"id":"lyon-2020","doi":"10.1002/ejhf.1920","pmid":"32458582","title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","source":"Eur J Heart Fail. 2020;22(11):1945-1960","authors":"Lyon AR, Dent S, Stanway S, et al."},"age_years":50,"components":[{"tier":"very_high","factor":"heart_failure_or_cardiomyopathy","points":0,"present":false},{"tier":"high","factor":"severe_valvular_heart_disease","points":0,"present":false},{"tier":"high","factor":"mi_or_coronary_revascularization","points":0,"present":false},{"tier":"high","factor":"stable_angina","points":0,"present":false},{"tier":"high","factor":"previous_anthracycline","points":0,"present":false},{"tier":"high","factor":"prior_left_chest_or_mediastinal_rt","points":0,"present":false},{"tier":"medium_1","factor":"elevated_troponin","points":0,"present":false},{"tier":"medium_1","factor":"elevated_bnp","points":0,"present":false},{"tier":"medium_1","factor":"hypertension","points":0,"present":false},{"tier":"medium_1","factor":"diabetes","points":0,"present":false},{"tier":"medium_1","factor":"ckd","points":0,"present":false},{"tier":"medium_1","factor":"previous_non_anthracycline_chemo","points":0,"present":false},{"tier":"medium_1","factor":"current_or_significant_smoker","points":0,"present":false},{"tier":"medium_1","factor":"obesity","points":0,"present":false},{"tier":"none","value":50,"factor":"age_years","points":0,"present":false},{"tier":"none","value":60,"factor":"lvef_percent","points":0,"present":false}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","risk_level":"low","lvef_percent":60,"medium_points":0,"formula_expression":"very_high if heart_failure_or_cardiomyopathy; else high if any High factor (severe_valvular_heart_disease, mi_or_coronary_revascularization, stable_angina, lvef_percent<50, age_years>=80, previous_anthracycline, prior_left_chest_or_mediastinal_rt) OR medium_points>=5; else medium if medium_points in 2..4; else low (no factors or one Medium 1). medium_points sums Medium 1 (=1: elevated_troponin, elevated_bnp, hypertension, diabetes, ckd, previous_non_anthracycline_chemo, current_or_significant_smoker, obesity) and Medium 2 (=2: lvef_percent 50-54, age_years 65-79) only. Age and LVEF use the highest matching printed band. Lyon 2020 HFA-ICOS anthracycline table. cardiotoxicity_guide is that paper's expert-opinion guide: low <2%, medium 2-9%, high 10-19%, very high >=20%","cardiotoxicity_guide":"<2%"}]}},"iconUrl":"https://api.magentlab.com/favicon.ico"},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"body":{"type":"object","required":["items"],"properties":{"items":{"type":"array","items":{"type":"object","required":["age_years","lvef_percent","heart_failure_or_cardiomyopathy","severe_valvular_heart_disease","mi_or_coronary_revascularization","stable_angina","previous_anthracycline","prior_left_chest_or_mediastinal_rt","elevated_troponin","elevated_bnp","hypertension","diabetes","ckd","previous_non_anthracycline_chemo","current_or_significant_smoker","obesity"],"properties":{"ckd":{"type":"boolean","description":"Chronic kidney disease (eGFR <60 mL/min/1.73 m2) as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not compute eGFR."},"obesity":{"type":"boolean","description":"Obesity (BMI >30 kg/m2) as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not compute BMI."},"diabetes":{"type":"boolean","description":"Diabetes mellitus (HbA1c >7.0% or >53 mmol/mol or on treatment) as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not assay HbA1c."},"age_years":{"type":"integer","description":"Age in years (18-100, integer). Lyon 2020: >=80 High; 65-79 Medium 2; <65 no age factor. Highest matching band only."},"elevated_bnp":{"type":"boolean","description":"Baseline BNP or NT-proBNP above the local laboratory ULN as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not assay natriuretic peptides."},"hypertension":{"type":"boolean","description":"Hypertension (SBP >140 mmHg or DBP >90 mmHg or on treatment) as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not measure blood pressure."},"lvef_percent":{"type":"integer","description":"LVEF percent (10-80, integer). Lyon 2020: <50 High; 50-54 Medium 2; >=55 no LVEF factor. Highest matching printed band only. magent does not read imaging."},"stable_angina":{"type":"boolean","description":"Stable angina (Lyon 2020 High). true or false as assigned by the caller. magent does not examine the patient."},"elevated_troponin":{"type":"boolean","description":"Baseline troponin above the local laboratory ULN as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not assay troponin."},"previous_anthracycline":{"type":"boolean","description":"Previous anthracycline exposure (Lyon 2020 High). true or false as assigned by the caller."},"current_or_significant_smoker":{"type":"boolean","description":"Current smoker or significant smoking history (Lyon 2020 Medium 1). true or false as assigned by the caller."},"severe_valvular_heart_disease":{"type":"boolean","description":"Severe valvular heart disease (Lyon 2020 High). true or false as assigned by the caller. magent does not examine the patient or read imaging."},"heart_failure_or_cardiomyopathy":{"type":"boolean","description":"Heart failure or cardiomyopathy (Lyon 2020 Very high). true or false as assigned by the caller. magent does not examine the patient or read imaging."},"mi_or_coronary_revascularization":{"type":"boolean","description":"Myocardial infarction or previous coronary revascularization (PCI or CABG) (Lyon 2020 High). true or false as assigned by the caller. magent does not read imaging."},"previous_non_anthracycline_chemo":{"type":"boolean","description":"Previous non-anthracycline-based chemotherapy (Lyon 2020 Medium 1). true or false as assigned by the caller."},"prior_left_chest_or_mediastinal_rt":{"type":"boolean","description":"Prior radiotherapy to the left chest or mediastinum (Lyon 2020 High). true or false as assigned by the caller."}}},"maxItems":25,"minItems":1}},"additionalProperties":false},"type":{"type":"string","const":"http"},"method":{"type":"string","const":"POST"},"headers":{"type":"object","additionalProperties":{"type":"string"}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}}}},"description":"Lyon 2020 HFA-ICOS baseline cardiovascular risk before anthracycline chemotherapy. Returns risk_level low, medium, high, or very_high from published Very high, High, Medium 2, and Medium 1 factors, plus medium_points and the paper's expert-opinion cardiotoxicity_guide. Age and LVEF use the highest matching printed band only. Caller assigns labs and BMI >30. magent does not examine the patient or read imaging. Not a medical device or treatment order.","lastUpdated":"2026-09-28T13:45:06.884Z","serviceName":"magent","x402Version":2}]}}